Skip to main content

Fiscal Wizard · Single-issue tearsheet

GDTC / Jun 21, 2026 Run #7553

GDTC

CytoMed Therapeutics Limited

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Composite verdict

F 14.1 / 100
Bearish setup · Trend Following 6 drivers · 2 gates blocking
  • Rate of Change
  • Coppock Curve
  • MACD Signal Cross
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 374th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 16 signals100% Bear
Momentum Bearish 3Mean-reversion Neutral 48

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -96%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

27.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Gross Margin 75
Margin of Safety 0
P/B 75
Free Cash Flow Yield 0
Days Sales Outstanding 0

Technicals Bearish

0.5 / 100

Bearish setup leads (Rate of Change, Coppock Curve, MACD Signal Cross); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 6
MACD Signal Cross 15
Coppock Curve 17

Risk Gates

2 blocking 6 caution

2 guards active, 25 signals gated.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Altman Z-Score Caution

Bottom-band Altman Z blocks bullish signals — distress risk.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for GDTC.